Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRC003
MIFTS: 53

Trichomoniasis

Categories: Infectious diseases, Nephrological diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Trichomoniasis

About this section

MalaCards integrated aliases for Trichomoniasis:

Name: Trichomoniasis 12 74 54 42 3 15 32
Trichomonas Infections 43 71
Trichomonas Infection 12 3

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Reproductive diseases Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1947
ICD9CM 34 131
MeSH 43 D014245
NCIt 49 C35720
SNOMED-CT 67 56335008
ICD10 32 A59 A59.9
UMLS 71 C0040921
Sources

Summaries for Trichomoniasis

About this section
MedlinePlus : 42 Trichomoniasis is a sexually transmitted disease caused by a parasite. It spreads from person to person during sex. Many people do not have any symptoms. If you do get symptoms, they usually happen within 5 to 28 days after being infected. It can cause vaginitis in women. Symptoms include Yellow-green or gray discharge from the vagina Discomfort during sex Vaginal odor Painful urination Itching burning, and soreness of the vagina and vulva Most men do not have symptoms. If they do, they may have Itching or irritation inside the penis Burning after urination or ejaculation Discharge from the penis Trichomoniasis can increase the risk of getting or spreading other sexually transmitted diseases. Pregnant women with trichomoniasis are more likely to give birth too early, and their babies are more likely have a low birth weight. Lab tests can tell if you have the infection. Treatment is with antibiotics. If you are infected, you and your partner must be treated. Correct usage of latex condoms greatly reduces, but does not eliminate, the risk of catching or spreading trichomoniasis. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. Centers for Disease Control and Prevention

MalaCards based summary : Trichomoniasis, also known as trichomonas infections, is related to pelvic inflammatory disease and oral candidiasis, and has symptoms including fever, pruritus and pelvic pain. An important gene associated with Trichomoniasis is IL2 (Interleukin 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Aztreonam and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include testes, cervix and prostate, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A parasitic protozoa infectious disease that is caused by singled-celled protozoan parasites Trichomonas vaginalis or Trichomonas tenax, which infect the urogenital tract and mouth respectively.

CDC : 3 Trichomoniasis (or "trich") is a very common sexually transmitted disease (STD). It is caused by infection with a protozoan parasite called Trichomonas vaginalis. Although symptoms of the disease vary, most people who have the parasite cannot tell they are infected.

Wikipedia : 74 Trichomoniasis (trich) is an infectious disease caused by the parasite Trichomonas vaginalis. About 70%... more...

Sources

Related Diseases for Trichomoniasis

About this section

Diseases related to Trichomoniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 601, show less)
# Related Disease Score Top Affiliating Genes
1 pelvic inflammatory disease 30.9 IL2 EPPIN CD40LG CD4
2 oral candidiasis 30.7 SLPI CXCL8 CD4
3 bacterial vaginosis 30.4 TNF LAP3 IL6 IL1B CXCL8
4 pyuria 30.4 IL6 CXCL8 CD40LG
5 genital herpes 30.4 CD40LG CD4 CCR5 ATAD2
6 chlamydia 30.2 TNF IL6 IL1B CXCL8 CD40LG
7 candidiasis 30.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
8 vaginitis 30.0 TNF SLPI LAP3 IL6 IL1B EPPIN
9 syphilis 30.0 TNF IL6 CD40LG CD4 CCR5
10 placenta disease 30.0 TNF IL6 IL1B CXCL8
11 salpingitis 30.0 TNF CD40LG CD4
12 cystitis 30.0 TNF IL6 IL2 CXCL8
13 urethritis 29.9 TNF IL6 IL1B CXCL8 CD40LG CD4
14 prostatitis 29.9 TNF IL6 IL1B CXCL8
15 bronchiectasis 29.9 TNF SLPI IL1B CXCL8
16 amebiasis 29.8 TNF IL1B CXCL8 CD40LG CD4
17 filariasis 29.8 TNF IL6 IL2
18 esophagitis 29.7 TNF IL6 IL1B CXCL8
19 human immunodeficiency virus infectious disease 29.7 TNF SLPI IL2 CD4 CCR5 CCL20
20 endometritis 29.7 TNF IL6 IL1B CXCL8
21 schistosomiasis 29.7 TNF LGMN IL2 CD40LG
22 erythema multiforme 29.6 TNF IL6 IL2 CXCL8
23 human immunodeficiency virus type 1 29.5 TNF SLPI IL2 CD4 CCR5
24 toxoplasmosis 29.5 TNF IL6 IL1B CD40LG CCR5
25 immune deficiency disease 29.4 TNF IL6 IL2 CD40LG CD4 CCR5
26 acute cystitis 29.4 TNF IL6 IL1B CXCL8 CD40LG CD4
27 acute pancreatitis 29.4 TNF IL6 IL1B CXCL8
28 rhinitis 29.4 TNF IL6 IL1B CXCL8
29 lung abscess 29.4 TNF IL6 IL1B CD40LG CD4
30 diarrhea 29.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
31 cervical cancer 29.3 TNF IL6 IL2 IL1B CXCL8 CD4
32 cervicitis 29.3 TNF IL6 IL2 IL1B CXCL8 CD4
33 trypanosomiasis 29.3 TNF IL6 IL2 IL1B CXCL8
34 vaginal discharge 29.3 TNF SLPI LAP3 IL6 IL1B CXCL8
35 chorioamnionitis 29.3 TNF SLPI IL6 IL1B CXCL8
36 sarcoidosis 1 29.0 TNF IL2 IL1B CD40LG CD4 CCR5
37 cystic fibrosis 28.9 TNF SLPI IL6 IL1B CXCL8 CD4
38 cellulitis 28.9 TNF IL6 IL2 IL1B CD40LG CD4
39 bacterial infectious disease 28.9 TNF IL6 IL1B CXCL8 CD40LG CD4
40 pharyngitis 28.9 TNF IL6 IL1B CXCL8 CD40LG CD4
41 fungal infectious disease 28.7 TNF IL6 IL2 IL1B CXCL8 CD40LG
42 stomatitis 28.7 TNF IL6 IL2 IL1B CXCL8 CD40LG
43 peripheral nervous system disease 28.7 TNF IL6 IL2 IL1B CXCL8 CD40LG
44 leishmaniasis 28.6 TNF LMLN IL6 IL2 IL1B CXCL8
45 parasitic protozoa infectious disease 28.3 TNF LMLN IL6 IL2 IL1B CXCL8
46 vaginal disease 28.1 TNF SLPI IL6 IL2 IL1B CXCL8
47 trichomonas vaginalis trichomoniasis 12.6
48 trichomonas tenax trichomoniasis 12.5
49 dientamoebiasis 11.8
50 infertility 10.5
51 cork-handlers' disease 10.5 CD40LG CD4
52 abacavir allergy 10.4 CD4 CCR5
53 american histoplasmosis 10.4 CD40LG CD4
54 syphilitic meningitis 10.4 CD40LG CD4
55 vulvovaginal candidiasis 10.4
56 vulvovaginitis 10.4
57 bagassosis 10.4 IL1B CXCL8
58 giardiasis 10.4
59 campylobacteriosis 10.4
60 tuberculoid leprosy 10.4 IL2 CD40LG CD4
61 periapical granuloma 10.4 IL2 CXCL8 CCR5
62 acute transverse myelitis 10.4 IL6 CXCL8
63 early yaws 10.4 CD40LG CD4
64 anemia, autoimmune hemolytic 10.3 IL2 CD40LG CD4
65 t cell deficiency 10.3 IL2 CD40LG CD4
66 leukorrhea 10.3
67 asymptomatic neurosyphilis 10.3 CD40LG CD4
68 wells syndrome 10.3 IL2 IL1B CXCL8
69 thymus gland disease 10.3 IL2 CD40LG CD4
70 thymus cancer 10.3 IL2 CD40LG CD4
71 west nile encephalitis 10.3 CD40LG CD4 CCR5
72 secondary syphilis 10.3 CD40LG CD4 CCR5
73 chancroid 10.3 CD40LG CD4 CCR5
74 west nile fever 10.3 CD40LG CD4 CCR5
75 relapsing polychondritis 10.3 IL6 IL2 CXCL8
76 latent syphilis 10.3 CD40LG CD4
77 capillary leak syndrome 10.3 IL6 IL2 CXCL8
78 ocular toxoplasmosis 10.3 CD40LG CCR5
79 gastroduodenitis 10.3 CD40LG CD4
80 fuchs' heterochromic uveitis 10.3 IL6 CXCL8
81 primary syphilis 10.3 CD40LG CD4
82 immune-complex glomerulonephritis 10.3 CD40LG CD4 CCR5
83 transient arthritis 10.2 CD40LG CD4
84 prosthetic joint infection 10.2 IL6 IL1B
85 herpes simplex 10.2
86 cowpox 10.2 IL6 CXCL8 CD4
87 periodontitis, chronic 10.2 IL6 IL1B
88 norwegian scabies 10.2 CD40LG CD4
89 interstitial cystitis 10.2 IL6 IL2 CXCL8
90 cervical adenitis 10.2 IL1B CD40LG CD4
91 necrotizing ulcerative gingivitis 10.2 CD40LG CD4
92 chronic meningitis 10.2 IL1B CD40LG CD4
93 bacterial conjunctivitis 10.2 IL1B CXCL8 CD40LG
94 uremic pruritus 10.2 IL6 IL2 IL1B
95 neuroretinitis 10.2 CD40LG CD4
96 endocrine exophthalmos 10.2 IL6 CD40LG
97 polyclonal hypergammaglobulinemia 10.2 IL6 CD40LG CD4
98 indolent myeloma 10.2 IL6 IL1B
99 urethral syndrome 10.2 IL6 CXCL8 CD4
100 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
101 erythema elevatum diutinum 10.2 CXCL8 CD40LG
102 diabetes mellitus, insulin-dependent, 23 10.2 TNF CD4
103 skin sarcoidosis 10.2 TNF IL2 CD4
104 recurrent corneal erosion 10.2 IL6 IL1B CXCL8
105 superficial basal cell carcinoma 10.2 TNF IL2 CD4
106 physiological polycythemia 10.2 TNF IL1B
107 toxicodendron dermatitis 10.2 TNF IL2 CXCL8
108 oral tuberculosis 10.2 TNF IL2 CD4
109 babesiosis 10.2 IRF6 CD40LG CD4
110 rheumatoid arthritis interstitial lung disease 10.1 TNF CD4
111 conjunctivochalasis 10.1 IL6 IL1B CXCL8
112 bacteriuria 10.1 IL6 CXCL8 CD40LG
113 viral meningitis 10.1 IL6 CXCL8 CD40LG
114 ascaris lumbricoides infection 10.1 IL6 IL1B CXCL8
115 pericardial effusion 10.1 IL6 CD40LG CD4
116 external pathological resorption 10.1 TNF IL6
117 clonorchiasis 10.1 TNF IL2 CXCL8
118 plasma cell neoplasm 10.1 IL6 CXCL8 CD40LG
119 systemic onset juvenile idiopathic arthritis 10.1 TNF IL1B
120 scorpion envenomation 10.1 TNF IL6
121 haemophilus influenzae 10.1 TNF CXCL8
122 pleural tuberculosis 10.1 TNF CXCL8 CD4
123 staphylococcal toxic shock syndrome 10.1 TNF IL1B
124 mesangial proliferative glomerulonephritis 10.1 IL6 CD40LG CCR5
125 carpal tunnel syndrome 10.1 IL6 IL2 IL1B
126 mastitis 10.1 SLPI IL6 CXCL8
127 endogenous depression 10.1 IL6 IL2 IL1B
128 aspiration pneumonia 10.1
129 pleural empyema 10.1
130 tracheitis 10.1
131 cytokine deficiency 10.1
132 overgrowth syndrome 10.1
133 pleurisy 10.1 TNF IL2 CXCL8
134 sialadenitis 10.1 TNF CD4 CCL20
135 allergic conjunctivitis 10.1 TNF IL2 CXCL8
136 vulvar vestibulitis syndrome 10.1 TNF IL1B
137 mature b-cell neoplasm 10.1 IL6 IL2 CD40LG CD4
138 palladium allergic contact dermatitis 10.1 TNF IL1B
139 coccidioidomycosis 10.1 TNF CD40LG CD4
140 cervix uteri carcinoma in situ 10.1
141 cervical intraepithelial neoplasia 10.1
142 angioimmunoblastic lymphadenopathy with dysproteinemia 10.1 TNF IL6
143 kashin-beck disease 10.1 TNF IL1B
144 extrinsic allergic alveolitis 10.1 IL6 IL1B CXCL8
145 opportunistic bacterial infectious disease 10.0 TNF CD40LG CD4
146 gastrointestinal tuberculosis 10.0 TNF CD40LG CD4
147 cerebritis 10.0 TNF CD40LG CD4
148 granulomatous hepatitis 10.0 TNF CD40LG CD4
149 mononeuritis of upper limb and mononeuritis multiplex 10.0 TNF CD40LG CD4
150 mononeuritis multiplex 10.0 TNF CD40LG CD4
151 necrotizing fasciitis 10.0 IL6 IL2 IL1B CXCL8
152 granulomatous dermatitis 10.0 TNF CD40LG CD4
153 abdominal tuberculosis 10.0 TNF CD40LG CD4
154 farmer's lung 10.0 TNF SLPI IL2 CD4
155 duodenitis 10.0 TNF CD40LG CD4
156 good syndrome 10.0 TNF CD40LG CD4
157 miliary tuberculosis 10.0 TNF CD40LG CD4
158 choroiditis 10.0 TNF CD40LG CD4
159 taeniasis 10.0 TNF CD40LG CD4
160 metal allergy 10.0 TNF IL1B CD4
161 acute proliferative glomerulonephritis 10.0 TNF CD40LG CD4
162 retinal vasculitis 10.0 TNF CD40LG CD4
163 facial nerve disease 10.0 TNF CD40LG CD4
164 pustulosis palmaris et plantaris 10.0 TNF CD40LG CCL20
165 newborn respiratory distress syndrome 10.0 IL6 IL1B EPPIN CXCL8
166 histoplasmosis 10.0 TNF CD40LG CD4
167 pulmonary sarcoidosis 10.0 TNF IL2 CCR5
168 poliomyelitis 10.0 TNF CD40LG CD4
169 idiopathic anterior uveitis 10.0 TNF IL6 CXCL8
170 neuromyelitis optica 10.0 IL6 IL1B CD40LG
171 hypopyon 10.0 TNF IL6 CD4
172 thyroiditis 10.0 TNF IL6 IL2
173 acute myocarditis 10.0 TNF IL1B CD4
174 cardiac sarcoidosis 10.0 TNF IL1B CXCL8
175 autoimmune pancreatitis 10.0 TNF CD40LG CD4
176 yellow fever 10.0 IL6 IL1B CCR5
177 transverse myelitis 10.0 TNF IL6 CXCL8
178 opisthorchiasis 10.0 TNF IL1B CXCL8
179 microscopic colitis 10.0 TNF IL6 IL2
180 mucocutaneous leishmaniasis 10.0 TNF LMLN IL2 CD4
181 dermatitis herpetiformis 10.0 TNF CXCL8 CD40LG
182 alpha-1-antitrypsin deficiency 10.0 TNF SLPI CXCL8
183 progressive myoclonus epilepsy 8 10.0 TNF IL6 CXCL8
184 intestinal perforation 10.0 TNF IL6 CD4
185 childhood type dermatomyositis 10.0 TNF IL6 CD4
186 cardiomyopathy, familial hypertrophic, 20 10.0 TNF IL6 CXCL8
187 extrapulmonary tuberculosis 10.0 TNF IL1B CD4
188 posterior uveitis 10.0 TNF IL6 IL2
189 subacute sclerosing panencephalitis 10.0 TNF IL6 IL2
190 cyclic neutropenia 10.0 TNF IL1B CXCL8
191 allergic hypersensitivity disease 10.0 TNF IL2 CXCL8 CD4
192 vitreous disease 10.0 TNF IL6 CXCL8
193 localized scleroderma 10.0 TNF IL6 IL2
194 meconium aspiration syndrome 10.0 TNF IL6 CXCL8
195 nail disease 9.9 TNF IL6 CD4
196 cysticercosis 9.9 IL6 IL1B CD40LG CD4
197 fibrosis of extraocular muscles, congenital, 1 9.9
198 schistosoma mansoni infection, susceptibility/ 9.9
199 kala-azar 1 9.9
200 alacrima, achalasia, and mental retardation syndrome 9.9
201 ectopic pregnancy 9.9
202 anogenital venereal wart 9.9
203 male infertility 9.9
204 balanitis 9.9
205 esophageal candidiasis 9.9
206 urinary schistosomiasis 9.9
207 impotence 9.9
208 pancreatitis 9.9
209 endocervicitis 9.9
210 actinomycosis 9.9
211 neuropathy 9.9
212 trichinosis 9.9
213 hypereosinophilic syndrome 9.9
214 47,xyy 9.9
215 48,xyyy 9.9
216 leukoplakia 9.9
217 inflammatory myopathy with abundant macrophages 9.9
218 spinal cord injury 9.9 TNF IL6 CXCL8
219 severe cutaneous adverse reaction 9.9 TNF CD40LG CD4
220 rosacea 9.9 TNF IL6 CXCL8
221 central nervous system lymphoma 9.9 TNF IL6 IL2
222 silicosis 9.9 TNF IL1B CXCL8
223 progressive multifocal leukoencephalopathy 9.9 TNF IL2 CD40LG CD4
224 muckle-wells syndrome 9.9 TNF IL1B CXCL8
225 autoimmune vasculitis 9.9 TNF IL2 IL1B CD4
226 smallpox 9.9 TNF IL2 IL1B
227 hemorrhagic cystitis 9.9 TNF IL2 IL1B CD4
228 cryptogenic organizing pneumonia 9.9 TNF CXCL8 CD40LG CD4
229 pulmonary alveolar proteinosis 9.9 TNF IL6 CXCL8
230 hepatitis a 9.9 TNF IL1B CXCL8
231 tenosynovitis 9.9 TNF IL6 CD40LG
232 crohn's colitis 9.9 TNF IL2 IL1B CXCL8
233 african tick-bite fever 9.9 TNF IL6 CD40LG
234 anaerobic pneumonia 9.9 TNF IL6 IL1B
235 stachybotrys chartarum 9.9 TNF IL6 IL1B
236 ebola hemorrhagic fever 9.9 CD40LG CD4 CCL4L1
237 conjunctivitis 9.9 TNF IL6 IL2 CXCL8
238 scrub typhus 9.9 TNF IL1B CD40LG
239 eales disease 9.9 TNF IL6 IL1B
240 streptococcal toxic-shock syndrome 9.9 TNF IL6 IL2 CXCL8
241 omenn syndrome 9.9 TNF IL2 CD40LG CD4
242 carbuncle 9.9 TNF IL6 IL1B
243 chemical colitis 9.9 TNF IL6 IL1B
244 severe congenital neutropenia 9.9 TNF SLPI IL2 IL1B
245 penile disease 9.9 TNF IL6 IL2 CD4
246 eyelid disease 9.9 TNF LTB4R CD4
247 hypersensitivity vasculitis 9.9 TNF IL6 CD40LG
248 peptic ulcer disease 9.9 TNF IL1B CXCL8
249 background diabetic retinopathy 9.9 TNF IL6 IL1B
250 portal hypertension 9.9 TNF CXCL8 CD40LG CD4
251 shigellosis 9.9 TNF IL1B CXCL8
252 fasciitis 9.9 TNF IL6 IL2 CXCL8
253 hypersensitivity reaction type iii disease 9.9 TNF IL6 CD40LG
254 acute kidney tubular necrosis 9.9 TNF IL6 CD40LG
255 glossitis 9.9 TNF IL6 IL1B
256 subacute thyroiditis 9.9 TNF IL6 IL1B
257 lymphadenitis 9.9 TNF IL1B CXCL8 CD4
258 mycoplasma pneumoniae pneumonia 9.9 TNF IL6 CD40LG
259 autoimmune lymphoproliferative syndrome 9.8 TNF IL2 CD40LG CD4
260 decubitus ulcer 9.8 TNF IL6 IL1B
261 keratoconjunctivitis 9.8 TNF IL6 IL2 CXCL8
262 obstructive jaundice 9.8 TNF IL6 IL2 CXCL8
263 encephalomalacia 9.8 TNF IL6 IL1B
264 chronic recurrent multifocal osteomyelitis 9.8 TNF IL6 IL1B
265 echinococcosis 9.8 TNF IL6 CD40LG
266 multicentric carpotarsal osteolysis syndrome 9.8 TNF IL6 IL1B
267 hepatic vascular disease 9.8 TNF IL6 CD40LG
268 monoclonal gammopathy of uncertain significance 9.8 TNF IL6 CD40LG
269 lichen planus 9.8 TNF IL6 IL2 CXCL8
270 cytomegalovirus retinitis 9.8 TNF CD40LG CD4 CCR5
271 bronchiolitis obliterans 9.8 TNF SLPI IL6 CXCL8
272 chronic ulcer of skin 9.8 TNF IL6 IL1B
273 gingival overgrowth 9.8 TNF IL6 IL2 CXCL8
274 bone deterioration disease 9.8 TNF IL6 IL1B
275 leukostasis 9.8 TNF IL6 IL1B
276 autoimmune uveitis 9.8 TNF IL2 IL1B CCR5
277 ischemic bone disease 9.8 TNF IL6 IL1B
278 ureteral disease 9.8 TNF IL6 IL1B
279 mixed connective tissue disease 9.8 TNF IL6 CD40LG
280 neonatal jaundice 9.8 TNF IL6 IL1B
281 intermediate uveitis 9.8 TNF IL6 IL2 CCR5
282 somatoform disorder 9.8 TNF IL6 IL1B
283 rheumatic heart disease 9.8 TNF IL6 IL1B
284 granulomatosis with polyangiitis 9.8 TNF CD40LG CD4 CCR5
285 tularemia 9.8 TNF IL1B CD40LG CD4
286 pulmonary edema 9.8 TNF IL1B CXCL8
287 varicose veins 9.8 TNF IL6 CXCL8
288 purpura 9.8 TNF IL6 CD40LG
289 bone structure disease 9.8 TNF IL6 IL1B
290 ileitis 9.8 TNF IL6 CD4 CCR5
291 cholestasis 9.8 TNF SLPI LAP3 IL6
292 paracoccidioidomycosis 9.8 TNF IL6 IL2 CD40LG
293 rheumatic fever 9.8 TNF IL6 IL2 CD40LG
294 blastomycosis 9.8 TNF IL6 CD40LG CD4
295 aseptic meningitis 9.8 TNF IL1B CXCL8 CD40LG
296 iritis 9.8 TNF IL6 CD40LG CD4
297 pyoderma 9.8 TNF IL1B CXCL8 CD40LG
298 iridocyclitis 9.8 TNF IL6 CD40LG CD4
299 diphtheria 9.8 TNF IL2 IL1B CD40LG
300 avian influenza 9.8 TNF IL6 CXCL8 CCR5
301 fungal meningitis 9.8 TNF IL6 CD40LG CD4
302 hantavirus hemorrhagic fever with renal syndrome 9.8 TNF IL6 CD40LG CD4
303 arteriovenous malformation 9.8 TNF IL6 IL1B
304 autoimmune disease of peripheral nervous system 9.8 TNF IL6 CD40LG CD4
305 endocarditis 9.8 TNF IL6 CXCL8
306 suppression of tumorigenicity 12 9.8 TNF IL6 CXCL8 CD4
307 chikungunya 9.8 TNF IL6 IL1B
308 plasma protein metabolism disease 9.8 TNF IL6 CD40LG CD4
309 autoimmune disease of cardiovascular system 9.8 TNF IL6 CD40LG CD4
310 poems syndrome 9.8 TNF IL6 IL2 IL1B
311 panuveitis 9.8 TNF IL6 CD40LG CD4
312 autoimmune disease of exocrine system 9.8 TNF IL6 CD40LG CD4
313 nervous system disease 9.7 TNF IL6 IL1B CD4
314 ileus 9.7 TNF IL6 IL1B
315 pneumonic tularemia 9.7 TNF IL6 IL1B CD4
316 graft-versus-host disease 9.7 TNF IL6 IL2 IL1B
317 sleep disorder 9.7 TNF IL6 IL1B
318 cranial nerve disease 9.7 TNF IL6 CD40LG CD4
319 myelitis 9.7 TNF IL6 CXCL8 CD40LG
320 mental depression 9.7 TNF IL6 IL1B
321 blepharitis 9.7 TNF IL6 IL1B CD4
322 gastritis 9.7 TNF IL6 IL1B CXCL8
323 bronchiolitis 9.7 TNF IL6 CXCL8 CD40LG
324 spondyloarthropathy 9.7 TNF IL6 IL2 IL1B
325 dengue hemorrhagic fever 9.7 TNF IL6 CXCL8 CD40LG
326 potocki-shaffer syndrome 9.7 TNF IL6 CD40LG CD4
327 peptic esophagitis 9.7 TNF IL6 IL1B CXCL8
328 irritant dermatitis 9.7 TNF IL6 IL1B CXCL8
329 ectodermal dysplasia 1, hypohidrotic, x-linked 9.7 TNF IL6 IL1B CD4
330 periapical periodontitis 9.7 TNF IL6 IL1B CXCL8
331 periodontitis 9.7 TNF IL6 IL1B CXCL8
332 vaccinia 9.7 TNF IL6 IL2 CCR5
333 trachoma 9.7 TNF LTB4R IL6
334 dental pulp disease 9.7 TNF IL6 IL1B CXCL8
335 funisitis 9.7 TNF IL6 IL1B CXCL8
336 cholangitis, primary sclerosing 9.7 TNF IL6 CD40LG CD4
337 macular retinal edema 9.7 TNF IL6 IL1B CXCL8
338 salmonellosis 9.7 TNF IL6 IL1B CD4
339 endometrial disease 9.7 TNF IL6 IL1B CXCL8
340 pulpitis 9.7 TNF IL6 IL1B CXCL8
341 bile duct disease 9.7 TNF IL6 CD40LG CD4
342 pulmonary tuberculosis 9.7 TNF IL6 IL2 IL1B
343 perinatal necrotizing enterocolitis 9.7 TNF IL6 IL1B CXCL8
344 adult-onset still's disease 9.7 TNF IL6 IL1B CXCL8
345 sebaceous gland disease 9.7 TNF IL6 IL1B CXCL8
346 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 9.7 TNF IL6 IL1B CD4
347 periodic fever, familial, autosomal dominant 9.7 TNF IL6 IL1B CXCL8
348 apnea, obstructive sleep 9.7 TNF IL6 IL1B CXCL8
349 septic arthritis 9.7 TNF IL6 IL1B CXCL8
350 cytomegalovirus infection 9.7 TNF IL6 IL1B CXCL8
351 bacterial sepsis 9.7 TNF IL6 IL1B CXCL8
352 preterm premature rupture of the membranes 9.7 TNF IL6 IL1B CXCL8
353 leukemia, acute monocytic 9.7 TNF IL6 IL1B CXCL8
354 alopecia areata 9.7 TNF IL6 IL2 IL1B
355 aggressive periodontitis 9.7 TNF IL6 IL1B CXCL8
356 keratitis, hereditary 9.7 TNF IL6 IL1B CD4
357 gastric ulcer 9.7 TNF IL6 IL1B CXCL8
358 pyelonephritis 9.7 TNF IL6 IL1B CXCL8
359 herpes zoster 9.7 TNF IL2 CD40LG CD4 CCR5
360 duodenal ulcer 9.7 TNF IL6 IL1B CXCL8
361 pneumoconiosis 9.7 TNF IL6 IL1B CXCL8
362 bacterial meningitis 9.7 TNF IL6 IL1B CXCL8
363 lens disease 9.7 TNF IL6 IL1B
364 alcoholic liver cirrhosis 9.7 TNF IL6 IL1B CXCL8
365 familial mediterranean fever 9.7 TNF IL6 IL1B CXCL8
366 proteasome-associated autoinflammatory syndrome 1 9.7 TNF IL6 IL1B CXCL8
367 atrophic gastritis 9.7 TNF IL6 IL1B CXCL8
368 retinal vascular disease 9.7 TNF IL6 IL1B CXCL8
369 synovitis 9.7 TNF IL6 IL1B CXCL8
370 chronic granulomatous disease 9.7 TNF IL1B CXCL8 CD40LG
371 chronic mucocutaneous candidiasis 9.7 TNF IL6 IL1B CD4
372 alcoholic hepatitis 9.7 TNF IL6 IL1B CXCL8
373 osteomyelitis 9.7 TNF IL6 IL1B CXCL8
374 fibromyalgia 9.7 TNF IL6 IL1B CXCL8
375 irritable bowel syndrome 9.7 TNF IL6 IL1B CXCL8
376 adult respiratory distress syndrome 9.7 TNF IL6 IL1B CXCL8
377 sleep apnea 9.7 TNF IL6 IL1B CXCL8
378 gastroenteritis 9.7 TNF IL6 IL1B CXCL8
379 hashimoto thyroiditis 9.7 TNF IL6 IL2 IL1B
380 toxic encephalopathy 9.7 TNF IL6 IL1B
381 monocytic leukemia 9.7 TNF IL6 IL1B CXCL8
382 gout 9.7 TNF IL6 IL1B CXCL8
383 visceral leishmaniasis 9.7 TNF LMLN IL2 IL1B CXCL8
384 aspergillosis 9.7 TNF IL6 IL1B CXCL8
385 myositis 9.7 TNF IL6 IL1B CXCL8
386 peritonitis 9.7 TNF IL6 IL1B CXCL8
387 pertussis 9.7 TNF IL6 IL1B CXCL8
388 gastroesophageal reflux 9.7 TNF IL6 IL1B CXCL8
389 cholera 9.7 TNF IL6 IL1B CXCL8
390 essential thrombocythemia 9.6 TNF IL6 CXCL8 CD40LG
391 glucose metabolism disease 9.6 TNF IL6 IL1B CD4
392 churg-strauss syndrome 9.6 TNF IL2 IL1B CXCL8 CD40LG
393 hyper ige syndrome 9.6 TNF IL6 CXCL8
394 cerebral palsy 9.6 TNF IL6 IL1B CXCL8
395 idiopathic neutropenia 9.6 TNF IL6 IL1B CD40LG
396 laryngitis 9.6 TNF IL6 IL1B CD40LG
397 acquired metabolic disease 9.6 TNF IL6 IL1B CD4
398 tendinitis 9.6 TNF IL6 IL1B CD40LG
399 polyradiculopathy 9.6 TNF IL6 IL1B CD40LG
400 atherosclerosis susceptibility 9.6 TNF IL6 IL1B CXCL8
401 scleral disease 9.6 TNF IL6 IL2 CD40LG CD4
402 chorioretinitis 9.6 TNF IL6 IL2 CD40LG CD4
403 fatty liver disease 9.6 TNF IL6 IL1B CXCL8
404 chickenpox 9.6 TNF IL6 IL2 CD40LG CD4
405 autoimmune disease of blood 9.6 TNF IL6 IL2 CD40LG CD4
406 herpangina 9.6 TNF IL6 IL2 CD40LG CD4
407 dengue shock syndrome 9.6 TNF IL6 IL1B CD40LG
408 cutaneous lupus erythematosus 9.6 TNF IL6 IL1B CD40LG
409 q fever 9.6 TNF IL6 IL1B CD40LG
410 b cell deficiency 9.6 TNF IL6 IL2 CD40LG CD4
411 salivary gland disease 9.6 TNF IL6 IL2 CD40LG CD4
412 cryoglobulinemia 9.6 TNF IL6 IL1B CD40LG
413 typhoid fever 9.6 TNF IL6 IL1B CD40LG
414 blood coagulation disease 9.6 TNF IL6 IL2 CD40LG CD4
415 blood platelet disease 9.6 TNF IL6 IL2 CD40LG CD4
416 lyme disease 9.6 TNF IL6 IL1B CD40LG
417 x-linked monogenic disease 9.6 TNF IL6 IL2 CD40LG CD4
418 autoimmune disease of eyes, ear, nose and throat 9.6 TNF IL6 IL2 IL1B CD4
419 brucellosis 9.6 TNF IL6 IL2 CXCL8 CD40LG
420 sudden infant death syndrome 9.6 TNF IL6 IL1B CXCL8
421 autoimmune gastritis 9.6 TNF IL6 IL2 IL1B CD4
422 epididymis disease 9.6 TNF IL6 EPPIN CD40LG CD4
423 listeriosis 9.6 TNF IL6 IL2 IL1B CD4
424 severe acute respiratory syndrome 9.6 TNF IL6 IL2 CXCL8 CD40LG
425 hypotrichosis 1 9.6 TNF IL6 IL2 IL1B CD4
426 viral pneumonia 9.6 TNF IL6 CXCL8 CD40LG CD4
427 obsessive-compulsive disorder 9.6 TNF IL6 IL1B CXCL8
428 dermatitis 9.6 TNF IL6 IL2 IL1B CXCL8
429 burning mouth syndrome 9.6 TNF IL6 IL2 IL1B CXCL8
430 coronavirus infectious disease 9.6 TNF IL6 CXCL8 CD40LG CD4
431 paranasal sinus disease 9.6 TNF IL6 CXCL8 CD40LG CD4
432 vascular disease 9.6 TNF IL6 IL2 CD40LG CD4
433 vein disease 9.6 TNF IL6 CXCL8 CD40LG CD4
434 complex regional pain syndrome 9.6 TNF IL6 IL2 IL1B CXCL8
435 aphthous stomatitis 9.6 TNF IL6 IL2 IL1B CXCL8
436 appendicitis 9.6 TNF IL6 IL2 IL1B CXCL8
437 tonsillitis 9.6 TNF IL6 IL2 IL1B CXCL8
438 chronic fatigue syndrome 9.6 TNF IL6 IL2 IL1B CXCL8
439 colitis 9.6 TNF IL6 IL2 IL1B CXCL8
440 chronic conjunctivitis 9.6 TNF IL6 IL1B CXCL8 CD4
441 blood group, globoside system 9.6 TNF IL6 IL1B CXCL8 CD4
442 endophthalmitis 9.6 TNF IL6 IL1B CXCL8 CD4
443 drug-induced lupus erythematosus 9.6 TNF IL6 IL1B CXCL8 CD4
444 gingival disease 9.6 TNF IL6 IL1B CXCL8 CD4
445 lacrimal apparatus disease 9.6 TNF IL6 IL1B CXCL8 CD4
446 common cold 9.6 TNF IL6 IL1B CXCL8 CD4
447 respiratory allergy 9.6 TNF IL6 IL1B CXCL8 CD4
448 allergic contact dermatitis 9.6 TNF IL6 IL1B CXCL8 CD4
449 pleural disease 9.6 TNF IL6 IL1B CXCL8 CD4
450 stomach disease 9.6 TNF IL6 IL1B CXCL8 CD4
451 narcolepsy 9.6 TNF IL6 IL2 IL1B CXCL8
452 corneal disease 9.6 TNF IL6 IL1B CXCL8 CD4
453 basal cell carcinoma 9.6 TNF IL6 IL2 IL1B CXCL8
454 ulcerative colitis 9.6 TNF IL6 IL2 IL1B CXCL8
455 polyneuropathy 9.6 TNF IL6 IL1B CD40LG
456 osteoarthritis 9.6 TNF IL6 IL1B CXCL8
457 arthritis 9.5 TNF IL6 IL1B CXCL8 CCL20
458 pneumocystosis 9.5 TNF IL6 CD40LG CD4 CCR5
459 intestinal disease 9.5 TNF IL6 IL1B CXCL8 CD4
460 amyloidosis 9.5 TNF IL6 IL1B CD40LG
461 bone disease 9.5 TNF SLPI IL6 IL1B CXCL8
462 sickle cell anemia 9.5 TNF IL6 CXCL8 CD40LG CCR5
463 pulmonary fibrosis, idiopathic 9.5 TNF IL6 IL1B CXCL8 CD4
464 erysipelas 9.5 TNF IL6 IL2 IL1B CD40LG
465 plasmodium vivax malaria 9.5 TNF IL6 IL2 IL1B CD40LG
466 optic neuritis 9.5 TNF IL6 IL1B CXCL8 CCR5
467 neuritis 9.5 TNF IL6 IL1B CXCL8 CCR5
468 reactive arthritis 9.5 TNF IL6 IL1B CXCL8 CCR5
469 takayasu arteritis 9.5 TNF IL6 IL2 IL1B CD40LG
470 rubella 9.5 TNF IL6 IL2 IL1B CD40LG
471 aortitis 9.5 TNF IL6 IL1B CD40LG CD4
472 central nervous system vasculitis 9.5 TNF IL6 IL1B CD40LG CD4
473 viral hepatitis 9.5 TNF IL6 IL2 IL1B CD40LG
474 myocarditis 9.5 TNF IL6 IL2 IL1B CD40LG
475 tetanus 9.5 TNF IL6 IL2 IL1B CD40LG
476 pericardium disease 9.5 TNF IL6 IL1B CD40LG CD4
477 meningoencephalitis 9.5 TNF IL6 IL1B CD40LG CD4
478 psoriatic arthritis 9.5 TNF IL6 IL2 IL1B CD40LG
479 temporal arteritis 9.5 TNF IL6 IL1B CD40LG CD4
480 liver disease 9.5 TNF SLPI IL6 IL1B CXCL8
481 pyelitis 9.5 TNF IL6 IL1B CXCL8 CD40LG
482 retinal vein occlusion 9.5 TNF IL6 IL1B CXCL8 CD40LG
483 optic nerve disease 9.5 TNF IL6 IL1B CD40LG CD4
484 systemic scleroderma 9.5 TNF IL6 IL1B CD40LG CD4
485 legionellosis 9.5 TNF IL6 IL1B CXCL8 CD40LG
486 lichen disease 9.5 TNF IL6 IL2 CXCL8 CD40LG CD4
487 common variable immunodeficiency 9.5 TNF IL6 IL2 IL1B CD40LG
488 interstitial lung disease 9.4 TNF IL6 IL1B CXCL8 CD40LG
489 gingivitis 9.4 TNF SLPI IL6 IL2 IL1B CXCL8
490 plasmodium falciparum malaria 9.4 TNF IL6 CD40LG
491 nasal cavity disease 9.4 TNF IL6 IL2 IL1B CXCL8 CD4
492 contact dermatitis 9.4 TNF IL6 IL2 IL1B CXCL8 CD4
493 central nervous system disease 9.4 TNF IL6 IL1B CCR5
494 hematologic cancer 9.4 TNF IL6 IL2 CD40LG CD4
495 encephalitis 9.4 TNF IL6 IL1B CD40LG CCR5
496 crohn's disease 9.4 TNF IL6 IL2 IL1B CXCL8 CD4
497 splenic disease 9.4 TNF LMLN IL6 IL2 CD40LG CD4
498 chronic kidney disease 9.4 TNF SLPI IL6 IL1B CCR5
499 autosomal genetic disease 9.4 TNF IL6 IL1B EPPIN CXCL8 CD4
500 aplastic anemia 9.4 TNF IL6 IL2 IL1B CXCL8 CD4
501 lymphoma, non-hodgkin, familial 9.4 TNF IL6 IL2 CD40LG CD4
502 sclerosing cholangitis 9.4 TNF IL6 IL2 CXCL8 CD40LG CCR5
503 cholangitis 9.4 TNF IL6 IL2 CXCL8 CD40LG CCR5
504 juvenile rheumatoid arthritis 9.4 TNF IL6 IL2 IL1B CXCL8 CCR5
505 uveitis 9.4 TNF IL6 IL2 IL1B CXCL8 CCR5
506 primary systemic mycosis 9.4 TNF IL6 IL2 IL1B CD40LG CD4
507 autoimmune disease of skin and connective tissue 9.4 TNF IL6 IL2 IL1B CD40LG CD4
508 autoimmune disease of endocrine system 9.4 TNF IL6 IL2 IL1B CD40LG CD4
509 spinal cord disease 9.4 TNF IL6 IL2 IL1B CD40LG CD4
510 lymph node disease 9.4 TNF IL6 IL2 IL1B CD40LG CD4
511 autoimmune disease of gastrointestinal tract 9.4 TNF IL6 IL2 IL1B CD40LG CD4
512 parasitic helminthiasis infectious disease 9.4 TNF IL6 IL2 IL1B CD40LG CD4
513 extrinsic cardiomyopathy 9.3 TNF IL6 IL2 IL1B CD40LG CD4
514 hair disease 9.3 TNF IL6 IL2 IL1B CD40LG CD4
515 kawasaki disease 9.3 TNF IL6 IL2 IL1B CD40LG CD4
516 pre-eclampsia 9.3 TNF IL6 IL1B CXCL8 CD40LG
517 x-linked recessive disease 9.3 TNF IL6 IL2 IL1B CD40LG CD4
518 bone resorption disease 9.3 TNF IL6 IL1B
519 myelofibrosis 9.3 TNF IL1B CXCL8 CD40LG
520 plague 9.3 TNF IL6 IL1B CD4 CCR5 CCL20
521 demyelinating disease 9.3 TNF IL6 IL2 IL1B CD40LG CD4
522 leptospirosis 9.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
523 mumps 9.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
524 immune system disease 9.3 TNF IL6 IL2 IL1B CD40LG CD4
525 toxic shock syndrome 9.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
526 relapsing-remitting multiple sclerosis 9.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
527 otitis media 9.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
528 meningitis 9.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
529 measles 9.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
530 neutropenia 9.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
531 chlamydia pneumonia 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
532 cecal disease 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
533 bronchopneumonia 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
534 streptococcus pneumonia 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
535 primary biliary cirrhosis 9.3 TNF IL6 IL2 IL1B CD40LG CD4
536 middle ear disease 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
537 endocardium disease 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
538 dysentery 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
539 viral encephalitis 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
540 bronchitis 9.3 TNF SLPI IL6 IL1B CXCL8 CD40LG
541 pericarditis 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
542 leukemia, chronic lymphocytic 9.3 TNF IL6 IL2 CD40LG CD4 CCR5
543 lipoprotein quantitative trait locus 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
544 respiratory failure 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
545 lymphoid interstitial pneumonia 9.3 TNF IRF6 IL6 IL2 CD40LG CD4
546 connective tissue disease 9.3 TNF IL6 IL1B CXCL8 CD40LG CD4
547 thrombocytopenia 9.3 TNF IL6 IL2 IL1B CXCL8 CD40LG
548 dermatitis, atopic 9.2 TNF IL6 IL2 IL1B CXCL8 CD4
549 chagas disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD4
550 intracranial berry aneurysm 9.2 TNF IL6 IL1B
551 orchitis 9.2 TNF IL6 IL2 IL1B EPPIN CD40LG
552 pancreatic adenocarcinoma 9.2 TNF IL6 IL2 IL1B CXCL8
553 testicular disease 9.2 TNF IL6 IL2 IL1B EPPIN CD40LG
554 pneumonia 9.2 TNF SLPI IL6 IL2 IL1B CXCL8
555 coccidiosis 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
556 conjunctival disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
557 opportunistic mycosis 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
558 exanthem 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
559 hypersensitivity reaction type iv disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
560 nose disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
561 commensal bacterial infectious disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
562 uveal disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
563 leprosy 3 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
564 autoimmune disease of musculoskeletal system 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
565 bronchial disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
566 leukocyte disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
567 autoimmune disease of central nervous system 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
568 bone inflammation disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
569 integumentary system disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
570 upper respiratory tract disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
571 malaria 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
572 bacterial pneumonia 9.2 TNF SLPI IL6 IL1B CXCL8 CD40LG
573 leukemia, acute myeloid 9.2 TNF IL6 IL2 IL1B CXCL8 CD4
574 cutaneous leishmaniasis 9.2 TNF LMLN IL6 IL2 IL1B CXCL8
575 myeloma, multiple 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
576 skin disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
577 eye disease 9.2 TNF IL6 IL2 IL1B CXCL8 CD40LG
578 osteoporosis 9.1 TNF SLPI IL6 IL2 IL1B CXCL8
579 acquired immunodeficiency syndrome 9.1 TNF IL6 IL2 IL1B CD40LG CD4
580 autoimmune disease 9.1 TNF IL6 IL2 IL1B CXCL8 CD40LG
581 psoriasis 9.1 TNF SLPI IL6 IL2 IL1B CXCL8
582 lung disease 9.1 TNF SLPI IL6 IL1B CXCL8 CD40LG
583 anus disease 9.1 TNF SLPI IL6 IL2 IL1B CXCL8
584 cone-rod dystrophy 2 9.0 TNF IRF6 IL6 IL2 CD40LG CD4
585 celiac disease 1 9.0 TNF LAP3 IL6 IL2 IL1B CXCL8
586 pulmonary disease, chronic obstructive 9.0 TNF SLPI IL6 IL1B CXCL8 CD4
587 heart disease 9.0 TNF IL6 IL1B CXCL8 CD40LG CD4
588 rectal disease 9.0 TNF IL6 IL2 IL1B CXCL8 CD40LG
589 primary bacterial infectious disease 9.0 TNF IL6 IL2 IL1B CXCL8 CD40LG
590 combined t cell and b cell immunodeficiency 9.0 TNF IL6 IL2 IL1B CXCL8 CD40LG
591 behcet syndrome 9.0 TNF IL6 IL2 IL1B CXCL8 CD40LG
592 viral infectious disease 9.0 TNF IL6 IL2 IL1B CXCL8 CD40LG
593 multiple sclerosis 8.9 TNF IL6 IL2 IL1B CXCL8 CD40LG
594 diabetes mellitus, type i 8.9 TNF IL6 IL2 IL1B CXCL8 CD40LG
595 hypertension, essential 8.9 TNF IL6 IL2 IL1B CXCL8 CD40LG
596 inflammatory bowel disease 8.9 TNF IL6 IL2 IL1B CXCL8 CD40LG
597 systemic lupus erythematosus 8.9 TNF IL6 IL2 IL1B CXCL8 CD40LG
598 diabetes mellitus 8.8 TNF SLPI IL6 IL2 IL1B CXCL8
599 rheumatoid arthritis 8.8 TNF IL6 IL2 IL1B CXCL8 CD40LG
600 fallopian tube disease 8.7 WASF3 TNF SLPI IL6 IL1B CXCL8
601 asthma 8.7 TNF LTB4R IL6 IL2 IL1B CXCL8

Comorbidity relations with Trichomoniasis via Phenotypic Disease Network (PDN): (showing 2, show less)


Acute Cystitis Hypertension, Essential

Graphical network of the top 20 diseases related to Trichomoniasis:



Diseases related to Trichomoniasis
Sources

Symptoms & Phenotypes for Trichomoniasis

About this section

UMLS symptoms related to Trichomoniasis:


fever, pruritus, pelvic pain

MGI Mouse Phenotypes related to Trichomoniasis:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCR5 CD4 CD40LG IL1B IL2 IL6
2 immune system MP:0005387 9.36 CCR5 CD4 CD40LG IL1B IL2 IL6
Sources

Drugs & Therapeutics for Trichomoniasis

About this section

Drugs for Trichomoniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 51, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
2
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ofloxacin Approved Phase 4 82419-36-1 4583
5
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
6
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
9
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
10 Respiratory System Agents Phase 4
11 Antidotes Phase 4
12 Expectorants Phase 4
13 Antioxidants Phase 4
14 Antiviral Agents Phase 4
15 N-monoacetylcystine Phase 4
16 Antibiotics, Antitubercular Phase 4
17 Protective Agents Phase 4
18 Alkylating Agents Phase 4
19 Cytochrome P-450 Enzyme Inhibitors Phase 4
20 Hormone Antagonists Phase 4
21 Hormones Phase 4
22 Anti-Infective Agents, Local Phase 4
23 Antifungal Agents Phase 4
24 Cytochrome P-450 CYP3A Inhibitors Phase 4
25 Clindamycin phosphate Phase 4
26 Clindamycin palmitate Phase 4
27
Secnidazole Approved Phase 3 3366-95-8
28
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
29
Metronidazole Approved Phase 3 443-48-1 4173
30
leucovorin Approved Phase 3 58-05-9 6006 143
31
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
32
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
34
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
35
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
36 Antiparasitic Agents Phase 3
37 Antiprotozoal Agents Phase 3
38 Anti-Infective Agents Phase 3
39 Anti-Bacterial Agents Phase 3
40 Vitamin B Complex Phase 3
41 Folic Acid Antagonists Phase 3
42 Fanasil, pyrimethamine drug combination Phase 3
43 Folate Phase 3
44 Vitamin B9 Phase 3
45 Antimalarials Phase 3
46
Titanium dioxide Approved Phase 2 13463-67-7
47 Pharmaceutical Solutions Phase 1
48
Terconazole Approved Early Phase 1 67915-31-5 441383
49
Ethanol Approved 64-17-5 702
50 Acidophilus
51 Contraceptive Agents

Interventional clinical trials:

(showing 52, show less)
# Name Status NCT ID Phase Drugs
1 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis Unknown status NCT03380793 Phase 4 morinidazole
2 Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
3 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Unknown status NCT03391440 Phase 4 morinidazole
4 Randomized Phase IV Trial of Metronidazole Single Dose Versus 7 Day Dose for Treatment of Trichomonas Vaginalis Among HIV-infected Women Completed NCT01018095 Phase 4 Metronidazole
5 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
6 A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
7 A Phase 3, Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® Granules Containing 2 Grams of Secnidazole for the Treatment of Trichomoniasis Completed NCT03935217 Phase 3 Secnidazole;Placebo
8 Trichomonas Vaginalis Repeat Infections Among HIV Negative Women Completed NCT01832480 Phase 3 MTZ 500 mg twice daily x 7 days;MTZ 2 g
9 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
10 Effects of Metronidazole Plus Intermittent Preventive Treatment of Malaria in Pregnancy on Birth Outcomes: a Randomised Controlled Trial in Zambia Recruiting NCT04189744 Phase 3 IPTp-sulphadoxine-pyrimethamine plus metronidazole;IPTp-dihydroartemisinin-piperaquine plus metronidazole;IPTp-sulphadoxine-pyrimethamine
11 Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis Completed NCT01361048 Phase 2 oral metronidazole;neo penotran forte;neo penotran forte once a day
12 A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
13 Prospective Study for Cost-Effectiveness Strategies to Improve Partner Notification: Female Trichomonas and Male Urethritis Studies Completed NCT00207467 Phase 2
14 HIV/STI Risk Reduction for Incarcerated Women With Interpersonal Violence Completed NCT01907126 Phase 2
15 A Brief, Clinic-Based, Safer Sex Program for Young African-American Men Completed NCT01439503 Phase 2
16 A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions Completed NCT01591889 Phase 1 Tinidazole;Tinidazole
17 STARS: Sistas Talking About Real Solutions Completed NCT01028157 Phase 1
18 Rapid HIV Testing and Counseling in High Risk Women in Shelters Completed NCT01866046 Phase 1
19 "A Comparison Study of the WaterWorks® Douching Device vs. Commercial OTC Douching Device for the Reduction or Abatement of Perceived Vaginal Odor With or Without Complaints of Discharge in Women With no Infectious Causes of Vaginitis" Unknown status NCT00417365
20 Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis Unknown status NCT02185456 Early Phase 1 750 mg metronidazole/ 200 mg miconazole vaginal suppository;Standard of care
21 Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users Unknown status NCT03261804
22 The Impact of Short-term Financial Incentives on Sexual Behavior and HIV Incidence Among Youth: Evidence From a Randomized Controlled Field Trial in Lesotho Unknown status NCT01589965 Early Phase 1
23 Control of Trichomoniasis - A Paradigm for STD Control Completed NCT00334555
24 "Solana™ Trichomonas Assay Field Study" Completed NCT02566447
25 Trichomoniasis: Genotype and Phenotype Correlations in African American Women Completed NCT00998530
26 Comparing NAAT Testing to Standard Methods in Diagnosis of Vaginal Infections in the General Gynecology and Vulvovaginal Referral Offices. Completed NCT02203942
27 Validity of Patient-Collected Wet Mounts Completed NCT02641717
28 Prospective Collection of Female First-catch Urine, Vaginal Swab, Endocervical Swab, and Cervical Specimens for Testing With the APTIMA Trichomonas Vaginalis Assay Completed NCT01427023
29 Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing: Meeting the Needs of an At-Risk Population Completed NCT00978848
30 Clinical Evaluation of the Click Sexual Health Test for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women Completed NCT04098900
31 A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test Completed NCT00682851
32 DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women Completed NCT01874158
33 A Validation Study of the Cepheid Xpert CT/NG for Detecting Chlamydia Trachomatis and Neisseria Gonorrhoeae in Rectal Samples Completed NCT02099760
34 Observational Program Neo-Penotran® Forte Completed NCT01335373 Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
35 Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network Completed NCT00503542 Early Phase 1 Terazol or oral fluconazole for candidal vaginitis;Metronidazole or Clindamycin for Bacterial Vaginosis;Flagyl for definitively diagnosed vaginal trichomoniasis
36 Sexually Transmitted Infections Among African American Women Who Have Sex With Women Completed NCT01546714
37 Prevalence Rates of Sexually Transmitted Infections and Sexual Risk Behaviors Among African American Women Who Have Sex With Women Completed NCT01043081
38 HIV Prevention Preparedness Study Completed NCT00048282
39 Pivotal Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women Completed NCT03852316
40 Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners Completed NCT01111721
41 Four-Arm RCT of Brief MI vs. Couples-Based HIV/STI Prevention in South Africa Completed NCT01554423
42 A Case Control Study of Women With Multiple Sexual Partners Attending the Jefferson County Department of Health Sexually Transmitted Diseases Clinic Completed NCT01578915
43 Changing the STI Care Model to Reduce Genital Inflammation and HIV Risk in South African Women Completed NCT03407586
44 Use of Condoms in Prevention of Progression of Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial. Completed NCT02907333
45 Evaluating a Microfinance Intervention for Vulnerable Women in Kazakhstan Completed NCT02406482
46 Repeat STI Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk Completed NCT01510262
47 Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy: A Randomized Placebo-controlled Double-blinded Trial Completed NCT03008421
48 Impact and Process Evaluation of Integrated Community and Clinic-based HIV-1 Control: a Cluster-randomised Trial in Eastern Zimbabwe Completed NCT00390949
49 Trichomonas Vaginalis Genotyping in Upper Egypt Not yet recruiting NCT03614286
50 Prospective Collection of Female First-catch Urine, Vaginal Swab,Cervical, and Endocervical Swab Specimens for Testing With the APTIMA Assays Terminated NCT01728103
51 Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs Terminated NCT03596151
52 Project AWARE: Using the ED to Prevent STIs in Youth Withdrawn NCT01195220

Search NIH Clinical Center for Trichomoniasis

Cochrane evidence based reviews: trichomonas infections

Sources

Genetic Tests for Trichomoniasis

About this section
Sources

Anatomical Context for Trichomoniasis

About this section

MalaCards organs/tissues related to Trichomoniasis:

40
Testes, Cervix, Prostate, Colon, Neutrophil, Skin, T Cells
Sources

Publications for Trichomoniasis

About this section

Articles related to Trichomoniasis:

(showing 3084, show less)
# Title Authors PMID Year
1
Development of a convenient detection method for Trichomonas vaginalis based on loop-mediated isothermal amplification targeting adhesion protein 65. 61 42
32357839 2020
2
IL-6 produced by prostate epithelial cells stimulated with Trichomonas vaginalis promotes proliferation of prostate cancer cells by inducing M2 polarization of THP-1-derived macrophages. 42
32196489 2020
3
Protozoan genital invasions caused by the representatives of trichomonas and giardia. 42
32248179 2020
4
Comparison between secretory leukocytic protease inhibitor and reactive nitrogen intermediates levels in cervicovaginal secretions from symptomatic and asymptomatic trichomoniasis Egyptians patients. 54 61
17153694 2006
5
Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. 61 54
9728551 1998
6
Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis. 61
32515610 2020
7
Actin Gene-Based Molecular Typing of Trichomonas vaginalis Clinical Isolates from the North of Iran. 61
32500506 2020
8
Proteomic signatures of metronidazole-resistant Trichomonas vaginalis reveal novel proteins associated with drug resistance. 61
32487244 2020
9
Trichomonas vaginalis NTPDase inhibited by lycorine modulates the parasite-neutrophil interaction. 61
32524267 2020
10
Data showing differential expression of Monocyte chemoattractant protein-1 in response to symptomatic and asymptomatic T. vaginalis infection. 61
32395589 2020
11
Ethnic variations in sexual partnerships and mixing, and their association with STI diagnosis: findings from a cross-sectional biobehavioural survey of attendees of sexual health clinics across England. 61
31422350 2020
12
The effect of iron on Trichomonas vaginalis TvCP2: a cysteine proteinase found in vaginal secretions of trichomoniasis patients. 61
32174285 2020
13
Developing a new drug against trichomoniasis, new inhibitory compounds of the protein triosephosphate isomerase. 61
32112829 2020
14
Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis among women with genitourinary infection and pregnancy-related complications in Tehran: A cross-sectional study. 61
32517577 2020
15
Early sex work initiation and its association with condomless sex and sexually transmitted infections among female sex workers in Iran. 61
32538329 2020
16
Trichomoniasis in a tertiary hospital of Madrid, Spain (2013-2017): prevalence and pregnancy rate, coinfections, metronidazole resistance, and endosymbiosis. 61
32405804 2020
17
Vaginal probiotic adherence and acceptability in Rwandan women with high sexual risk participating in a pilot randomised controlled trial: a mixed-methods approach. 61
32434932 2020
18
Gellan gum-based hydrogel containing nanocapsules for vaginal indole-3-carbinol delivery in trichomoniasis treatment. 61
32473199 2020
19
STI prevalence among women at risk for HIV exposure initiating safer conception care in rural, southwestern Uganda. 61
32404858 2020
20
Characterising HIV and STIs among transgender female sex workers: a longitudinal analysis. 61
32366602 2020
21
Trichomonas vaginalis in Pregnancy: Patterns and Predictors of Testing, Infection, and Treatment. 61
32282605 2020
22
Response to letter of comments: Comments on a retrospective epidemiological analysis of shared risk factors for bovine trichomoniasis and bovine genital campylobacteriosis in La Pampa province (Argentina). Highlighting a neglected agent: Leptospira sp. 61
31492445 2020
23
Call to action for health systems integration of point-of-care testing to mitigate the transmission and burden of sexually transmitted infections. 61
32241905 2020
24
HIV Testing Among Adolescents With Acute Sexually Transmitted Infections. 61
32179661 2020
25
Technologies, strategies and approaches for testing populations at risk of sexually transmitted infections: a systematic review protocol to inform prevention and control in EU/EEA countries. 61
32213195 2020
26
Diagnostic evaluation of the BD Affirm VPIII assay as a point-of-care test for the diagnosis of bacterial vaginosis, trichomoniasis and candidiasis. 61
32050856 2020
27
PCR Detection and Sequencing of Trichomonas vaginalis in Women with Suspected Vaginitis in the southwestern Iran. 61
32072909 2020
28
2'-Hydroxychalcones as an alternative treatment for trichomoniasis in association with metronidazole. 61
31853622 2020
29
Noncandidal vaginitis: a comprehensive approach to diagnosis and management. 61
31513780 2020
30
Multimodality Screening for Lower Genital Tract Infections Between 18 and 24 Weeks of Pregnancy and its Efficacy in Predicting Spontaneous Preterm Delivery. 61
32030004 2020
31
Antimicrobial resistance in sexually transmitted infections. 61
31840758 2020
32
Declining trends in HIV and other sexually transmitted infections among female sex workers in Iran could be attributable to reduced drug injection: a cross-sectional study. 61
31836679 2020
33
Antiparasitic activity of furanyl N-acylhydrazone derivatives against Trichomonas vaginalis: in vitro and in silico analyses. 61
32046788 2020
34
Impact of Symbiosis Between Trichomonas vaginalis and Mycoplasma hominis on Vaginal Dysbiosis: A Mini Review. 61
32457847 2020
35
Trichomonas Vaginalis Infection Among Women Attending Laboratory Centers in Ilam, Iran. 61
30652653 2020
36
Vaginal dysbiotic bacteria act as pathobionts of the protozoal pathogen Trichomonas vaginalis. 61
31669328 2020
37
Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. 61
31992328 2020
38
Fortuitous diagnosis of Trichomoniasis by PCR using panfungal primers. 61
31726227 2020
39
Clinical Validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: Results from a Prospective Multicenter Clinical Study. 61
31748322 2020
40
School suspension predicts trichomoniasis five years later in a matched sample. 61
31959144 2020
41
The association between region of birth and sexually transmitted infections among people of black Caribbean ethnicity attending sexual health services in England, 2015. 61
32084155 2020
42
Diagnostic performance of two molecular assays for the detection of vaginitis in symptomatic women. 61
31502121 2020
43
[Evaluation of Microscopic Examination, Culture and Polymerase Chain Reaction Tests in the Diagnosis of Trichomonas vaginalis Infection]. 61
32050884 2020
44
Is there association between Trichomonas vaginalis infection and prostate cancer risk?: A systematic review and meta-analysis. 61
31539586 2019
45
Efficacy of netropsin dihydrochloride against the viability, cytopathogenicity and hemolytic activity of Trichomonas vaginalis clinical isolates. 61
31189504 2019
46
Composite thermoresponsive hydrogel with auranofin-loaded nanoparticles for topical treatment of vaginal trichomonad infection. 61
32377561 2019
47
Prevalence of double-stranded RNA virus in Trichomonas vaginalis isolated in Italy and association with the symbiont Mycoplasma hominis. 61
31701295 2019
48
Major factors associated to persistence of bovine trichomoniasis in a mandatory control plan: A eight year retrospective study in La Pampa, Argentine. 61
31796194 2019
49
Reduced Trichomonas vaginalis viability in mice pretreated with parasite DNA. 61
31391128 2019
50
20S Proteasome as a Drug Target in Trichomonas vaginalis. 61
31451503 2019
51
Pharmacokinetic and Pharmacodynamic Effects of Metronidazole May Account for the Superior Efficacy of Multidose Therapy Among Women With Trichomoniasis. 61
31644503 2019
52
Trichomonas vaginalis Virus Among Women With Trichomoniasis and Associations With Demographics, Clinical Outcomes, and Metronidazole Resistance. 61
30768180 2019
53
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. 61
29685081 2019
54
Comments on a retrospective epidemiological analysis of shared risk factors for bovine trichomoniasis and bovine genital campylobacteriosis in La Pampa province (Argentina). Highlighting a neglected agent: Leptospira sp. 61
31484084 2019
55
STI update: Testing, treatment, and emerging threats. 61
31710586 2019
56
Trichomonas vaginalis, endometritis and sequelae among women with clinically suspected pelvic inflammatory disease. 61
31719170 2019
57
Borderline personality disorder is associated with an increased risk of sexually transmitted infections: A nationwide population-based cohort study in Taiwan. 61
30981998 2019
58
In Vitro Activity of Foeniculum vulgare and Its Main Essential Oil Component Trans-Anethole on Trichomonas vaginalis. 61
32099566 2019
59
Discovery of Ligand-Efficient Scaffolds for the Design of Novel Trichomonas vaginalis Uridine Nucleoside Ribohydrolase Inhibitors Using Fragment Screening. 61
31592163 2019
60
Recent Advances in the Discovery of Novel Antiprotozoal Agents. 61
31661934 2019
61
Modeling Public Health Campaigns for Sexually Transmitted Infections via Optimal and Feedback Control. 61
31302875 2019
62
Compliance and Treatment Outcomes of Various Regimens for Trichomoniasis in Trinidad and Tobago. 61
31547105 2019
63
Refocusing Research on Sexually Transmitted Infections. 61
31495889 2019
64
Hormonal Contraception and Vaginal Infections Among Couples Who Are Human Immunodeficiency Virus Serodiscordant in Lusaka, Zambia. 61
31403592 2019
65
Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention. 61
31524362 2019
66
Prevalence of vulvovaginal candidiasis, bacterial vaginosis and trichomoniasis in pregnant women attending antenatal clinic in the middle belt of Ghana. 61
31547803 2019
67
Molecular Diagnosis of Vaginitis: Comparing Quantitative PCR and Microbiome Profiling Approaches to Current Microscopy Scoring. 61
31315951 2019
68
Increased intracellular Cl- concentration mediates Trichomonas vaginalis-induced inflammation in the human vaginal epithelium. 61
31254529 2019
69
Anti-Trichomonas vaginalis activity of 1,10-phenanthroline-5,6-dione-based metallodrugs and synergistic effect with metronidazole. 61
30207253 2019
70
Trichomonas vaginalis and Mycoplasma hominis: new tales of two old friends. 61
30616707 2019
71
Addressing the constraints of Tritrichomonas foetus sample collection in remote areas: lyophilized modified Diamond's media as a substitute for liquid medium. 61
30859924 2019
72
Design and Application of a High-Throughput, High-Content Screening System for Natural Product Inhibitors of the Human Parasite Trichomonas vaginalis. 61
31265248 2019
73
Zinc-clotrimazole complexes are effective against Trichomonas vaginalis. 61
31046845 2019
74
Management of Resistant Trichomoniasis. 61
31388764 2019
75
Evaluation of reliability of self-collected vaginal swabs over physician-collected samples for diagnosis of bacterial vaginosis, candidiasis and trichomoniasis, in a resource-limited setting: a cross-sectional study in India. 61
31462459 2019
76
Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. 61
31384073 2019
77
HQSAR and random forest-based QSAR models for anti-T. vaginalis activities of nitroimidazoles derivatives. 61
31100677 2019
78
Prevalence of reproductive tract infections in women attending a tertiary care center in Northern India with special focus on associated risk factors. 61
31922100 2019
79
Trichomonas vaginalis Detection in Female Specimens with cobas® TV/MG for use on the cobas® 6800/8800 Systems. 61
31223495 2019
80
Genetic Diversity of Trichomonas Vaginalis Clinical Isolates According to Restriction Fragment Length Polymorphism Analysis of the 60-kDa Proteinase Gene. 61
31165993 2019
81
Pentamycin Biosynthesis in Philippine Streptomyces sp. S816: Cytochrome P450-Catalyzed Installation of the C-14 Hydroxyl Group. 61
31095370 2019
82
Acceptability, tolerability, and effects on symptoms and signs of vulvovaginitis of a non-soap, herbal-based intimate hygiene solution (Zelesse®). 61
31088247 2019
83
Is It Time to Stop Using Single-dose Oral Metronidazole for the Treatment of Trichomoniasis in Women? 61
30657463 2019
84
Accuracy of the BD MAX™ vaginal panel in the diagnosis of infectious vaginitis. 61
30685805 2019
85
Symptomatic Vaginal Infection by Neisseria meningitidis Resulting in Meningitis with Septic Shock. 61
31061974 2019
86
Sexually Transmitted Diseases in the Emergency Department. 61
30940365 2019
87
Hormonal Contraceptives and the Acquisition of Sexually Transmitted Infections: An Updated Systematic Review. 61
30628946 2019
88
Trichomonas vaginalis virus: a review of the literature. 61
30626281 2019
89
Prevalence and Genotyping of Trichomonas vaginalis Infected to dsRNA Virus by PCR-Restriction Fragment Length Polymorphism (RFLP). 61
31543913 2019
90
The Role of Iron Status in the Early Progression of Metronidazole Resistance in Trichomonas vaginalis Under Microaerophilic Conditions. 61
30047563 2019
91
Ligand-Efficient Inhibitors of Trichomonas vaginalis Adenosine/Guanosine Preferring Nucleoside Ribohydrolase. 61
30701958 2019
92
Antiparasitic activity of synthetic curcumin monocarbonyl analogues against Trichomonas vaginalis. 61
30594049 2019
93
In vitro anti-Trichomonas vaginalis activity of Haplophyllum myrtifolium. 61
32040454 2019
94
Cooperative Interactions between Trichomonas vaginalis and Associated Bacteria Enhance Paracellular Permeability of the Cervicovaginal Epithelium by Dysregulating Tight Junctions. 61
30858343 2019
95
Incidence and predictors of reinfection with trichomoniasis based on nucleic acid amplification testing results in HIV-infected patients. 61
30486764 2019
96
Aptima Trichomonas vaginalis assay elucidates significant underdiagnosis of trichomoniasis among women in Brazil according to an observational study. 61
30154157 2019
97
Controlled delivery of the antiprotozoal agent (tinidazole) from intravaginal polymer matrices for treatment of the sexually transmitted infection, trichomoniasis. 61
29799300 2019
98
Sexually Transmitted Infection Among Adolescents and Young Adults With Bipolar Disorder: A Nationwide Longitudinal Study. 61
30901168 2019
99
Infection with Trichomonas vaginalis increases the risk of psychiatric disorders in women: a nationwide population-based cohort study. 61
30867042 2019
100
Evaluation of the BD MAX™ Vaginal Panel for the detection of vaginal infections in a sexual health service in the UK. 61
30931826 2019
101
Trichomonas vaginalis and HIV infection acquisition: a systematic review and meta-analysis. 61
30341233 2019
102
Immune Response of BALB/c Mice toward Putative Calcium Transporter Recombinant Protein of Trichomonas vaginalis. 61
30840797 2019
103
Epinecidin-1: A marine fish antimicrobial peptide with therapeutic potential against Trichomonas vaginalis infection in mice. 61
30552913 2019
104
Anti-Trichomonas vaginalis activity of chalcone and amino-analogues. 61
30535524 2019
105
Trichomonicidal activity of a new anthraquinone isolated from the roots of Morinda panamensis Seem. 61
30570769 2019
106
Comparison of Two PCR Assays for Trichomonas vaginalis. 61
30840796 2019
107
Transmission electron microscopy revealing the mechanism of action of photodynamic therapy on Trichomonas vaginalis. 61
30447179 2019
108
Age-related variation in the oral microbiome of urban Cooper's hawks (Accipiter cooperii). 61
30791867 2019
109
Chemotherapeutic options for the treatment of human trichomoniasis. 61
30612993 2019
110
Calophyllum inophyllum in vaginitis treatment: Stimulated by electroporation with an in vitro approach. 61
30465335 2019
111
Comparison of Seropositivity to Trichomonas vaginalis between Men with Prostatic Tumor and Normal Men. 61
30840795 2019
112
Acute epididymo-orchitis: relevance of local classification and partner's follow-up. 61
31720038 2019
113
Synthesis and modification of crystalline SBA-15 nanowhiskers as a pH-sensitive metronidazole nanocarrier system. 61
30448312 2019
114
Demonstration and Characterization of Cyst-Like Structures in the Life Cycle of Trichomonas vaginalis. 61
32010634 2019
115
Trichomonas vaginalis and Mycoplasma infections among women with vaginal discharge at Fann teaching hospital in Senegal. 61
31161092 2019
116
A novel 6-pyrophosphorylating IP6 kinase (IP6-6K) discovered in the protozoon Trichomonas vaginalis. 61
30593849 2019
117
A Study of Trichomonas vaginalis Infection and Correlates in Women with Vaginal Discharge Referred at Fann Teaching Hospital in Senegal. 61
31057956 2019
118
Trichomonas vaginalis triggers the release of THP-1 extracellular traps. 61
30426227 2019
119
Prevalence and cervical organism burden among Louisiana women with Trichomonas vaginalis infections. 61
31220094 2019
120
Medicinal Plants with Anti-Trichomonas vaginalis Activity in Iran: A Systematic Review. 61
31123463 2019
121
Trichomonas vaginalis Induces NLRP3 Inflammasome Activation and Pyroptotic Cell Death in Human Macrophages. 61
30391945 2019
122
Treatment recommendations for trichomoniasis in women. 61